中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

休市中 10-23 16:08:09

5.000

+0.020

+0.40%

最高5.050	最低4.865	成交量6,409万
今开4.990	昨收4.980	日振幅3.71%
总市值934.15亿	流通市值934.15亿	总股本186.83亿
成交额3.18亿	换手率0.34%	流通股本186.83亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":5,"timestamp":1792742889003,"preClose":4.98,"halted":0,"volume":64094780,"delay":0,"changeRate":0.004016064257028026,"floatShares":18683000000,"shares":18683000000,"eps":0.1526331515610173,"marketStatus":"休市中","change":0.02,"latestTime":"10-23 16:08:09","open":4.99,"high":5.05,"low":4.865,"amount":318076123,"amplitude":0.037149,"askPrice":5,"askSize":660000,"bidPrice":4.995,"bidSize":108000,"shortable":3,"etf":0,"ttmEps":0.15611387274238703,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792978200000},"marketStatusCode":7,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":4.98,"dividendRate":0.024663,"openAndCloseTimeList":[[1792719000000,1792728000000],[1792731600000,1792742400000]],"volumeRatio":0.9046292596247218,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.4856,"impliedVolPercentile":0.8367},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"2677894498","title":"中国生物制药TQB2102 HER2低表达乳腺癌Ⅲ期研究入选ESMO年会优选口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2677894498","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677894498?lang=zh_cn&edition=full","pubTime":"2026-10-23 16:19","pubTimestamp":1792743540,"startTime":"0","endTime":"0","summary":"中国生物制药TQB2102 HER2低表达乳腺癌Ⅲ期研究入选ESMO年会优选口头报告","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610233906297656.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610233906297656.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01177","IE00BZ08YS42.EUR","BK1515","BK1521","BK1589","BK1191","HK0000165453.HKD","IE00BZ08YT58.USD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176338505","title":"中国生物制药：10月22日回购1000万股，耗资约4977.80万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176338505","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176338505?lang=zh_cn&edition=full","pubTime":"2026-10-22 16:51","pubTimestamp":1792659096,"startTime":"0","endTime":"0","summary":"2026年10月22日，中国生物制药有限公司（01177）公告披露，当日公司于香港联合交易所场内回购普通股1000万股，占已发行股本约0.054%，每股回购价格介乎4.955港元至4.98港元，合计涉资约4977.80万港元。\n回购完成后，公司已发行股份总数仍为18,682,952,230股，库藏股数目维持为0股。购回授权于2026年6月17日获通过，可购回股份总数为1,870,501,723股，截至目前已累计回购45,953,000股，占授权总数约0.246%。公司确认此次回购符合香港联合交易所上市规则及相关法律法规的规定。公告由公司秘书赖娟签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"中国生物制药：10月22日回购1000万股，耗资约4977.80万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677122958","title":"中国生物制药(01177)10月22日斥资4977.8万港元回购1000万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2677122958","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677122958?lang=zh_cn&edition=full","pubTime":"2026-10-22 16:49","pubTimestamp":1792658993,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，于2026年10月22日斥资4977.8万港元回购1000万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1510775.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","IE00BZ08YT58.USD","BK1521","IE00BZ08YR35.GBP","01177","HK0000165453.HKD","BK1191","BK1589","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176653351","title":"异动解读｜中国生物制药盘中下跌3.27%，鼻息肉新药III期完成入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1176653351","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176653351?lang=zh_cn&edition=full","pubTime":"2026-10-22 10:17","pubTimestamp":1792635451,"startTime":"0","endTime":"0","summary":"10月22日，中国生物制药盘中下跌3.27%，报5.175港元，成交额6279.18万港元。消息面上，公司日前公告，附属正大天晴自主研发的TQC2731注射液用于慢性鼻窦炎伴鼻息肉维持治疗的III期注册临床试验已完成全部参与者入组。TQC2731为TSLP单抗，被公司称为首个进入III期临床的国产TSLP单抗；公告称其通过拮抗TSLP，有望同时调控2型与非2型炎症，具备差异化开发潜力。此次进展属于研发节点更新，但仍待后续临床数据及注册推进进一步验证。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"中国生物制药下跌，鼻息肉新药III期完成入组","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677642431","title":"【券商聚焦】中泰国际：创新药与医疗AI技术出海捷报频传","url":"https://stock-news.laohu8.com/highlight/detail?id=2677642431","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677642431?lang=zh_cn&edition=full","pubTime":"2026-10-21 13:28","pubTimestamp":1792560508,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际表示，中国创新药企业继2026年上半年出海金额同比增加36%至1,200亿美元后，下半年仍然捷报频出。港股上市的企业中，9月恒瑞医药9月与诺和诺德达成总额最高26亿美元的授权协议后，创新药龙头翰森制药与AI技术平台开发商剂泰科技近日分别与礼来及罗氏达成战略合作。该机构重申聚焦创新药龙头观点，并看好中国AI制药新技术。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994121","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","LU0228659784.USD","BK1574","LU0502904849.HKD","LNGR","01177","LU1719994722.HKD","01801","BK1521","MEDX","LU0149534421.HKD","LU1807302812.USD","IE00BZ08YT58.USD","IBBQ","LU1951186391.HKD","LU1023057109.AUD","LU0140636845.USD","LU1008478684.HKD","LU0067412154.USD","IE00B5MMRT66.SGD","SG9999004220.SGD","IE00B031HY20.USD","06160","LU1831875114.USD","07666","BK1161","LU1813983027.USD","LU2488822045.USD","00013","LU1226287792.SGD","LU0359202008.SGD","LU0455707207.USD","LU0463099449.HKD","159992","KCE","LU1303224171.USD","LU2097828557.USD","LU0607220059.USD","LU2242644610.SGD","LU0828237510.HKD","KURE","01093","LU0244354667.USD","150261","IE00BZ08YS42.EUR","LU0072913022.USD","LU1188198961.HKD","06978","01276","LU1226287875.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677643406","title":"【券商聚焦】国金证券：创新药板块迎来业绩兑现与国际化重估共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2677643406","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677643406?lang=zh_cn&edition=full","pubTime":"2026-10-21 09:16","pubTimestamp":1792545406,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券研究指出，创新药前沿技术加速迭代，IO2.0、ADC迭代、自免长效双抗等重塑治疗格局。中国原研资产深度融入全球交易，国际化步入收获期。支付端医保与商保双轮驱动，国谈优化准入，商保目录落地缓解高值药进院约束，本土Biotech净现金流改善、迎来盈亏平衡拐点。海内外政策聚焦真创新，生物类似药温和集采兑现。优质管线梯队完备，百济神州、康方生物、科伦博泰等核心分子加速欧美商业化，创新药板块迎来业绩兑现与国际化重估共振。风险提示：BD受海外地缘政策约束风险；创新药行业竞争加剧风险；医保控费降价不及预期风险；海外流动性收紧风险。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994055","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","02269","06978","LU1770034418.SGD","LU1303224171.USD","BK1589","KURE","MEDX","LU0320764599.SGD","LU0455707207.USD","01093","09995","BK0183","LU0823426308.USD","IE00B031HY20.USD","LU1807302812.USD","IE00BPRC5H50.USD","01877","IE00B0JY6N72.USD","06185","LU0516422366.SGD","LU0128522744.USD","LU1951186391.HKD","06160","02142","IBBQ","LU0516422440.USD","09688","LNGR","LU0348783233.USD","600109","LU1226288170.HKD","KCE","LU2097828714.EUR","159992","BK1574","01177","LU0880133367.SGD","LU0456846285.SGD","02616","LU0348784397.USD","LU0417516571.SGD","LU0228659784.USD","09926","BK1141","LU0128526141.USD","IE0008368742.USD","LU0540923850.HKD","LU0588546209.SGD","LU1794554557.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677617702","title":"中国生物制药(01177.HK)：TQC2731注射液“TSLP单抗”慢性鼻窦炎伴鼻息肉III期注册临床完成全部参与者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2677617702","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677617702?lang=zh_cn&edition=full","pubTime":"2026-10-21 08:04","pubTimestamp":1792541053,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1515","01177","IE00BZ08YS42.EUR","BK1589","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1521","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100996497","title":"中国生物制药(01177)旗下TQC2731鼻息肉III期注册临床完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1100996497","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100996497?lang=zh_cn&edition=full","pubTime":"2026-10-21 07:55","pubTimestamp":1792540541,"startTime":"0","endTime":"0","summary":"2026年10月21日，中国生物制药有限公司发布自愿公告称，旗下子公司正大天晴药业集团股份有限公司自主研发的国家1类创新药TQC2731注射液用于慢性鼻窦炎伴鼻息肉维持治疗的III期注册临床试验已于近期完成全部参与者入组。公告指出，通过拮抗TSLP，TQC2731有望同时调控2型与非2型炎症，具备差异化开发潜力。公告称，该品种是首个进入III期临床试验的国产TSLP单抗，未来有望为更广泛的2型及非2型炎症患者提供新的治疗选择。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676669146","title":"中国生物制药靳松：ESG绝非品牌宣传工程，已经成为资本市场重要评估标尺","url":"https://stock-news.laohu8.com/highlight/detail?id=2676669146","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676669146?lang=zh_cn&edition=full","pubTime":"2026-10-20 17:24","pubTimestamp":1792488240,"startTime":"0","endTime":"0","summary":"作为集团ESG委员会主任，他明确，ESG绝非品牌宣传工程，已经成为资本市场重要评估标尺。ESG已经成为资本市场衡量一个企业是否具有高质量、可持续发展的重要评估模型和工具。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-10-20/doc-inivwiti7711248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000165453.HKD","IE00BZ08YT58.USD","BK1515","01177","159717","IE00BZ08YR35.GBP","PRXI","BK1589","BK1191","IE00BZ08YS42.EUR","BK1521","IVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676665575","title":"创新药概念强势 翰森制药（03692）涨逾7% 前三季对外技术授权约1300亿美元接近25年全年","url":"https://stock-news.laohu8.com/highlight/detail?id=2676665575","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676665575?lang=zh_cn&edition=full","pubTime":"2026-10-20 11:23","pubTimestamp":1792466598,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念强势，截至发稿，乐普生物 涨8.81%，翰森制药涨7.06%，药明生物涨6.74%，晶泰控股涨4.56%，康诺亚-B涨4.70%，亚盛医药涨4.30%，恒瑞医药涨4.16%，药明合联涨3.96%，云顶新耀涨3.89%，和黄医药涨3.68%，中国生物制药涨3.24%，石药集团涨3.16%，科伦博泰生物涨3.14%，诺诚健华涨3.08%。消息面上，据人民财讯，10月20日，国家发展改革委召开10月份新闻发布会，会上提到，我国前三季度创新药对外技术授权约1300亿美元，接近去年全年。","market":"nz","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993987","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","06978","LU0196878994.USD","BK1589","KURE","MEDX","02228","LU0417516738.SGD","01093","LU1242518857.USD","LU0043850808.USD","LU1008478684.HKD","LU2476274720.SGD","LU0348827113.USD","LU0128522744.USD","06855","LU0359201885.HKD","LU1242518931.SGD","IBBQ","LU0979878070.USD","00013","LU1188198961.HKD","LNGR","LU0417516902.SGD","LU1226288170.HKD","LU1152091754.HKD","02162","BK1610","159992","LU0052750758.USD","01177","01952","BK1576","BK1161","LU2543165471.USD","03692","LU1993786604.SGD","01276","02268","LU2488822045.USD","09969","LU1720050803.USD","LU0211977185.USD","IE0008369823.USD","06990","LU0072913022.USD","LU0588546209.SGD","LU1794554557.SGD","BK1521","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136022062","title":"异动解读｜中国生物制药盘中上涨3.43%，乙肝创新药临床结果将于AASLD公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1136022062","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136022062?lang=zh_cn&edition=full","pubTime":"2026-10-20 11:06","pubTimestamp":1792465592,"startTime":"0","endTime":"0","summary":"10月20日，中国生物制药盘中上涨3.43%，报5.43港元，成交额8844.17万港元。消息面上，公司此前披露，附属正大天晴自主研发的TQ-A3334二期临床研究入选美国肝病研究学会年会最新突破摘要，并将作口头报告；与GSK合作的Bepirovirsen亦入选2项口头报告及8项壁报展示，相关数据将于11月7日至11月8日公布。此外，公司10月13日及14日连续回购股份，合计回购1540万股，合计耗资约8079万港元，回购股份拟注销，对市场情绪亦形成一定支撑。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"中国生物制药上涨，乙肝新药数据将亮相AASLD","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142721322","title":"异动解读｜中国生物制药盘中上涨3.23%，乙肝创新药进展叠加回购提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1142721322","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142721322?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:38","pubTimestamp":1792114713,"startTime":"0","endTime":"0","summary":"10月16日，中国生物制药盘中上涨3.23%，报5.435港元，成交额3519.1万港元。消息面上，公司附属正大天晴的TQ-A3334临床结果入选美国肝病研究学会年会最新突破摘要，并将以口头报告公布；合作产品Bepirovirsen亦入选2项口头报告和8项壁报展示，市场对其乙肝创新管线关注升温。此外，公司10月14日回购800万股，耗资4132.32万港元，回购股份拟注销。叠加制药板块整体走强，石药集团、翰森制药、先声药业等同步上涨，带动股价共振走高。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"乙肝新药进展叠加回购，中国生物制药上涨","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675546035","title":"【券商聚焦】中信建投：ESMO中国研究入选创新高 梳理医药细分板块机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2675546035","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675546035?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:27","pubTimestamp":1792114033,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券表示，本周制药行业表现一般，2026 ESMO LBA中国研究入选创新高，恒瑞医药、康方生物、艾力斯等企业的管线迎来新进展。医疗器械及服务板块低值耗材表现较好，多受个股事件催化，科技概念标的调整，港股回购活跃；短期关注招标改善和集采出清，中长期看创新、出海、并购。中药板块跑赢申万医药及大盘，关注红利、创新及“四同药品”、中成药集采政策。生物制品板块跑输医药指数及大盘，AI制药、mRNA肿瘤疫苗概念股回调；南北方ILI%均环比降低，南方检测阳性率提升、北方降低。医药商业板块跑赢申万医药及大盘，药店关注三季度前瞻及集采进药店，流通关注回款及三季度前瞻。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993829","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","LU0228659784.USD","LU0819121731.USD","LU0314109678.HKD","LU0540923850.HKD","LU0181495838.USD","LU0979878070.USD","LU0348767384.USD","01177","02616","BK1500","601066","01801","LU0128526141.USD","LU0634319403.HKD","LU0348827113.USD","SG9999011746.SGD","BK1515","LU2476274720.SGD","LU1951186391.HKD","LU0140636845.USD","LU0823426480.USD","06185","06160","BK1583","BK1610","02269","09688","09995","LU0417516902.SGD","LU1242518857.USD","LU0359201612.USD","LU1226287792.SGD","BK1141","01877","IE00BZ08YR35.GBP","KCE","SG9999002562.SGD","LU0501845795.SGD","LU1251922891.USD","KURE","01093","LU0072913022.USD","09926","LU0326950275.SGD","159938","LU0052750758.USD","02142","09939","LU1226287875.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144206372","title":"异动解读｜中国生物制药盘中上涨3.1%，乙肝创新药进展叠加回购提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1144206372","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144206372?lang=zh_cn&edition=full","pubTime":"2026-10-15 10:24","pubTimestamp":1792031071,"startTime":"0","endTime":"0","summary":"10月15日，中国生物制药盘中上涨3.1%，报5.325港元，成交额1.32亿港元。消息面上，公司附属正大天晴的TQ-A3334临床结果入选美国肝病研究学会年会最新突破摘要，并将以口头报告公布；合作产品Bepirovirsen亦入选2项口头报告和8项壁报展示，强化市场对其乙肝创新管线的关注。同时，公司10月14日回购800万股，耗资4132.32万港元，回购股份拟注销。叠加当日创新药板块整体走强，中国生物制药股价随板块共振上行。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药走强，乙肝创新药与回购双催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675037153","title":"创新药概念走强 百济神州（06160）涨超4% 机构认为板块长期前景改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2675037153","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675037153?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:59","pubTimestamp":1792029581,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念走强，截至发稿，百济神州 涨4.11%，翰森制药涨3.14%，中国生物制药涨3.10%，再鼎医药涨2.80%，石药集团涨2.10%，科伦博泰生物涨2.06%。消息面上，里昂发表研究报告指，中国医疗保健板块处周期底部，管线进展有望提振情绪。中国创新资产为世界肺癌大会的重要亮点，料于欧洲肿瘤内科学会大会继续受关注；该行认为，目前各治疗领域的临床领先地位，将塑造未来市场份额。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993745","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","LU1251922891.USD","ONC","IE0008369823.USD","LNGR","LU1951186391.HKD","LU0072913022.USD","LU1008478684.HKD","LU1993786604.SGD","LU0501845795.SGD","LU1770034418.SGD","LU1226288253.USD","06160","IE00BZ08YT58.USD","688235","LU0140636845.USD","LU0228659784.USD","MEDX","BK0239","BK4588","01093","09688","159992","KURE","LU1152091168.USD","IE0008368742.USD","LU0307460666.USD","LU1813983027.USD","01177","LU0588546209.SGD","HK0000165453.HKD","BK4139","LU1960683339.HKD","SG9999004220.SGD","06990","BK4585","BK1515","LU2039709279.SGD","BK1521","LU2328871848.SGD","BK1588","BK1583","LU0828237510.HKD","06978","IBBQ","LU1719994722.HKD","BK1589","LU0314109678.HKD","LU0067412154.USD","LU1303224171.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675040379","title":"港股异动 | 中国生物制药(01177)涨近3% TQ-A3334及Bepirovirsen最新研究结果将于2026 AASLD公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2675040379","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675040379?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:48","pubTimestamp":1792028893,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国生物制药(01177)涨近3%，截至发稿，涨2.32%，报5.29港元，成交额4798.49万港元。消息面上，10月14日，中国生物制药发布公告，本集团附属公司正大天晴药业集团股份有限公司(正大天晴)自主研发的国家1类创新药TQ-A3334(TLR7激动剂)的一项临床研究结果，已入选2026年美国肝病研究学会(AASLD)年会最新突破摘要(late-breaking abstract，LBA)，并将以口头报告形式公布；正大天晴与葛兰素史克(GSK)战略合作产品Bepirovirsen(ASO)入选2项口头报告和8项壁报展示(包括1篇优秀壁报)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1507448.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","VXUS","IE00BZ08YS42.EUR","BK1191","BK1589","BK4585","01177","BK4588","BK1515","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1521","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675376082","title":"【券商聚焦】中信建投：AI重塑药物研发 2035年全球市场有望破460亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675376082","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675376082?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:00","pubTimestamp":1792026019,"startTime":"0","endTime":"0","summary":"AI深度介入靶点识别、分子设计等药物研发环节，破解传统制药高投入、长周期难题。报告测算，全球AI制药市场2025年规模约24.9亿美元，2035年有望突破460亿美元，CAGR超33%，国内市场具备高增长潜力；科技巨头、药企、CXO等多方入局，海内外多家头部企业完成平台搭建与商业化验证。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993729","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTOC","LU0128522744.USD","KURE","01801","02269","LU1251922891.USD","01877","09926","IE00B031HY20.USD","IE00BZ08YS42.EUR","LU0979878070.USD","LU0856984785.SGD","LU0456846285.SGD","LU0516423174.USD","LU0588546209.SGD","LU0348825331.USD","BK1141","LU0128526141.USD","01093","LU0456827905.SGD","02616","LU0029874061.USD","LU0052750758.USD","LU0501845795.SGD","LU1152091754.HKD","VTHR","BK1576","LU0516422952.EUR","LU0516422440.USD","601066","LU2778985437.USD","01177","09995","AGIX","LU2242644610.SGD","06185","BK1588","LU0051755006.USD","09688","LU0326950275.SGD","AIPO","CHAT","LU1008478684.HKD","02142","06160","ARTY","IBBJ","BK1500","KCE","SG9999002562.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101091535","title":"中国生物制药披露两款乙肝创新药最新临床进展 将亮相2026年AASLD年会","url":"https://stock-news.laohu8.com/highlight/detail?id=1101091535","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101091535?lang=zh_cn&edition=full","pubTime":"2026-10-14 18:25","pubTimestamp":1791973533,"startTime":"0","endTime":"0","summary":"中国生物制药有限公司10月14日公布，公司附属正大天晴药业集团股份有限公司自主研发的国家1类创新药TQ-A3334，以及与葛兰素史克合作的Bepirovirsen双双入选2026年美国肝病研究学会年会“最新突破摘要”与多项学术展示。相关研究数据将于2026年11月7日至11月8日在美国举行的年会上以口头报告及壁报形式发布。TQ-A3334的II期临床研究入选AASLD大会LBA环节。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675343650","title":"中国生物制药(01177.HK)：TQ-A3334“TLR7激动剂”及Bepirovirsen“ASO”最新研究结果将于2026 AASLD公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2675343650","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675343650?lang=zh_cn&edition=full","pubTime":"2026-10-14 18:24","pubTimestamp":1791973491,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1515","BK1589","HK0000165453.HKD","BK1521","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187750220","title":"中国生物制药10月14日回购8,000,000股，耗资41,323,200港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187750220","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187750220?lang=zh_cn&edition=full","pubTime":"2026-10-14 16:31","pubTimestamp":1791966696,"startTime":"0","endTime":"0","summary":"2026年10月14日，中国生物制药根据香港联交所《主板上市规则》要求，上载翌日披露报表。公司于当日于香港联交所场内回购8,000,000股普通股，占公司已发行股本约0.043%，每股回购价介乎5.175港元至5.155港元，合计耗资41,323,200港元。该批回购股份拟予以注销。根据公告，股东大会于2026年6月17日通过购回授权，授权公司可购回股本总数1,870,501,723股。另据公告，本次回购后至2026年11月13日期间，公司将暂缓任何新股发行或重新出售或转让库存股份的计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药10月14日回购8,000,000股，耗资41,323,200港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":-0.0476},{"period":"1month","weight":-0.1213},{"period":"3month","weight":-0.0165},{"period":"6month","weight":-0.0981},{"period":"1year","weight":-0.2681},{"period":"ytd","weight":-0.1711}],"compareEarnings":[{"period":"1week","weight":-0.0452},{"period":"1month","weight":-0.0701},{"period":"3month","weight":-0.0749},{"period":"6month","weight":-0.111},{"period":"1year","weight":-0.1107},{"period":"ytd","weight":-0.099}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.434783,"avgChangeRate":0.006945},{"month":2,"riseRate":0.652174,"avgChangeRate":0.056473},{"month":3,"riseRate":0.565217,"avgChangeRate":0.04606},{"month":4,"riseRate":0.478261,"avgChangeRate":0.020913},{"month":5,"riseRate":0.695652,"avgChangeRate":0.038341},{"month":6,"riseRate":0.347826,"avgChangeRate":0.004417},{"month":7,"riseRate":0.652174,"avgChangeRate":0.052281},{"month":8,"riseRate":0.434783,"avgChangeRate":-0.006702},{"month":9,"riseRate":0.434783,"avgChangeRate":-0.011268},{"month":10,"riseRate":0.521739,"avgChangeRate":0.018164},{"month":11,"riseRate":0.5,"avgChangeRate":0.067433},{"month":12,"riseRate":0.409091,"avgChangeRate":-0.011901}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SBP GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}